Compare GIFI & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIFI | SAVA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.0M | 156.5M |
| IPO Year | 1997 | N/A |
| Metric | GIFI | SAVA |
|---|---|---|
| Price | $11.96 | $2.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 169.0K | ★ 1.0M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $166,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.66 | ★ N/A |
| Revenue Growth | ★ 0.26 | N/A |
| 52 Week Low | $5.75 | $1.15 |
| 52 Week High | $12.00 | $4.98 |
| Indicator | GIFI | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 87.10 | 35.94 |
| Support Level | $11.92 | $1.96 |
| Resistance Level | $11.98 | $3.32 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 55.56 | 15.53 |
Gulf Island Fabrication Inc is a U.S. based company that is a fabricator of complex steel structures and marine vessels. The company also provides installation, hook-up, commissioning, repair, and maintenance services with specialized crews. The company operates through segments namely Fabrication division which fabricates structures such as offshore drilling and production platforms and other steel structures for customers in the oil and gas industries; the Shipyards division manufactures newly built and repairs various steel marine vessels in the United States; the Services division provides interconnect piping services on offshore platforms, welding, and inshore structures and also provides maintenance and industrial facilities. Majority revenue is from services segment.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.